Abstract: The National Comprehensive Cancer Network (NCCN) released the third version of Clinical Practice Guidelines in Gastric Cancer in 2025 (hereinafter referred to as the “updated guidelines”) on August 22,2025.Compared to the 2024 version,the updated guidelines integrate immune checkpoint inhibitors (ICIs) into the perioperative treatment of resectable gastric cancer,emphasize the early implementation of programmed death-ligand 1 (PD-L1) testing,and introduce new treatment regimens based on the results of multiple high-quality clinical studies published between 2024 and 2025.These updates signify a pivotal shift in the field of gastric cancer treatment toward a new developmental phase-one characterized by “biomarker-driven strategies,intensified combination therapies,and curative-intent approaches”.This article interprets the key updates in the guidelines by integrating recent research findings and revisions from other domestic and international guidelines.

Key words: gastric cancer, national comprehensive cancer network, guidelines, interpretation